Microbix Partners with Sekisui Diagnostics for COVID/Flu Test Quality Controls
The collaboration will provide quality assessment products to support the commercialization of a molecular point-of-care assay for COVID-19 and influenza detection.
The collaboration will provide quality assessment products to support the commercialization of a molecular point-of-care assay for COVID-19 and influenza detection.
The test measures microRNA-371a-3P biomarker and can guide treatment decisions while reducing need for some CT scans during surveillance.
UCLA Health researchers find cell-free DNA combined with machine learning can distinguish ALS from other neurological conditions.
The mass spectrometry-based assay achieved 100% sensitivity in detecting patients who later progressed to cancer in a blinded cohort study.
Single-button device designed to streamline workflow for PCR tuberculosis diagnostics in resource-limited settings, with potential deployment across India's primary health centers.
Researchers urge clinicians to integrate lipid management into prenatal care to mitigate elevated obstetric complications and cardiovascular risks.
From rising demand for comprehensive IgE profiles to the emergence of molecular allergen diagnostics, laboratories are central to how clinicians prepare for and manage September’s asthma spike.
Study of more than 13,000 individuals demonstrates improved precision for emergency department triage and patient outcomes.
Roche's Elecsys pTau181 assay gives clinical labs a key role in the initial evaluation of cognitive decline, helping to rule out amyloid pathology earlier in the diagnostic process.
The automated system uses ion exchange HPLC technology to deliver A1c results while detecting common hemoglobin variants.
The agreement aims to improve early detection and management of chronic kidney disease in underserved populations through integrated diagnostics and digital health solutions.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
TriVerity system demonstrated high sensitivity and specificity across more than 1,200 patients in pivotal SEPSIS-SHIELD trial.